When Dr. Hadiyah-Nicole Green receives invitations to be a guest speaker for professional groups, schools and nonprofit organizations, she almost never turns them down.
“Usually if there is an invitation to speak at a forum like that, I accept it because I feel like it’s a responsibility,” she said. “There are so few of us (black women in STEM fields) I don’t feel like I have the luxury to say I’m too busy.”
By many measures, Green has been extremely busy. One of fewer than 100 black female physicists in the country, she recently won a $1.1 million grant to further develop her patent-pending technology for using laser-activated nanoparticles to treat cancer.
Green earned her master’s and Ph.D degrees at the University of Alabama at Birmingham, and is now is an assistant professor in the physics department at Tuskegee University.
Green’s personal history with cancer fuels her drive to find a way to treat it. She grew up in St. Louis and – after the death of her mother and father – was raised by her aunt and uncle, General Lee Smith and his wife, Ora Lee.
When Ora Lee was diagnosed with cancer, “She refused the treatment because she didn’t want to experience the side effects,” said Green. “It was heartbreaking, but I could appreciate she wanted to die on her own terms. “Three months later, my uncle was diagnosed with cancer.”
Green took time off from school to help him through chemotherapy and radiation treatments. “I saw first-hand how devastating it was, and I could understand why my aunt didn’t want to go through that.”
She earned a bachelor’s degree in physics with a concentration in fiberoptics, and then a full scholarship to UAB. She got the idea to use lasers to treat cancer without the side effects of chemo and radiation.
A physicist’s cancer treatment
A few months ago, Green was awarded a $1.1 million grant to work on a technology that targets, images and treats cancer. “I was completely overwhelmed with joy, with thanksgiving, humbled at the opportunity that a group of my peers thought that my work was worthy for such a grant,” she said. “This is a huge door opening. It outlines a path to take this treatment to clinical trial.”